News Galectin Therapeutics Inc.

Equities

GALT

US3632252025

Real-time Estimate Cboe BZX Other stock markets 10:54:37 2024-04-18 am EDT			5-day change	1st Jan Change
3.295 ^USD	-2.51%		-21.90%	+97.59%

Mar. 29	Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	CI
Mar. 29	Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galectin Therapeutics : Corporate Presentation, April 2024	Apr. 17	PU
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension	Apr. 10	AQ
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis	Apr. 09	AQ
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	Apr. 01	AQ
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update	Mar. 29	AQ
Galectin Therapeutics Inc. Appoints Benjamin S. Carson as Member of the Board of Directors	Mar. 29	CI
Galectin Therapeutics : Reports 2023 Financial Results and Provides Business Update - Form 8-K	Mar. 29	PU
Galectin Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development	Mar. 12	AQ
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update	Nov. 13	AQ
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
North American Morning Briefing : Stock Futures -2-	Nov. 13	DJ
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD	Nov. 03	AQ
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023	23-10-23	AQ
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors	23-10-12	AQ
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension	23-10-04	AQ
Galectin Says Data and Safety Monitoring Board Approves Continuation of Belapectin Study Without Modifications.	23-10-03	MT
Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis	23-10-03	AQ
Galectin Therapeutics, Inc. Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE	23-10-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Galectin Therapeutics Inc.

Equities

GALT

US3632252025

Summary

Filters